Lactiga is a biotherapeutics company developing first-in-class mucosal antibody replacement therapies using secretory IgA (sIgA) purified from human milk. Its lead product, LCTG-001, is a nasal sIgA therapy for Common Variable Immune Deficiency (CVID), a rare disease with no approved IgA treatment. Backed by issued patents, FDA Orphan Drug and Rare Pediatric Disease designations, Lactiga is advancing LCTG-001 toward Phase II clinical development.